BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15781325)

  • 1. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.
    Hornebeck W; Lambert E; Petitfrère E; Bernard P
    Biochimie; 2005; 87(3-4):377-83. PubMed ID: 15781325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival.
    Lambert E; Bridoux L; Devy J; Dassé E; Sowa ML; Duca L; Hornebeck W; Martiny L; Petitfrère-Charpentier E
    Int J Biochem Cell Biol; 2009 May; 41(5):1102-15. PubMed ID: 19010442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
    Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
    Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis.
    Milner JM; Rowan AD; Cawston TE; Young DA
    Arthritis Res Ther; 2006; 8(5):R142. PubMed ID: 16919164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue inhibitor of matrix metalloproteinase-1 suppresses apoptosis of mouse bone marrow stromal cell line MBA-1.
    Guo LJ; Luo XH; Xie H; Zhou HD; Yuan LQ; Wang M; Liao EY
    Calcif Tissue Int; 2006 May; 78(5):285-92. PubMed ID: 16691494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
    O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
    Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
    Gomez DE; Alonso DF; Yoshiji H; Thorgeirsson UP
    Eur J Cell Biol; 1997 Oct; 74(2):111-22. PubMed ID: 9352216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
    Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
    Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities.
    Djafarzadeh R; Mojaat A; Vicente AB; von Lüttichau I; Nelson PJ
    Biol Chem; 2004 Jul; 385(7):655-63. PubMed ID: 15318815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells.
    Park HJ; Lee HJ; Min HY; Chung HJ; Suh ME; Park-Choo HY; Kim C; Kim HJ; Seo EK; Lee SK
    Eur J Pharmacol; 2005 Dec; 527(1-3):31-6. PubMed ID: 16309669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs correlates with outcome of acute experimental pseudomonal keratitis.
    Ikema K; Matsumoto K; Inomata Y; Komohara Y; Miyajima S; Takeya M; Tanihara H
    Exp Eye Res; 2006 Dec; 83(6):1396-404. PubMed ID: 16968651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
    Ramer R; Hinz B
    J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
    Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
    Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel functions of TIMPs in cell signaling.
    Chirco R; Liu XW; Jung KK; Kim HR
    Cancer Metastasis Rev; 2006 Mar; 25(1):99-113. PubMed ID: 16680576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing.
    Djafarzadeh R; Noessner E; Engelmann H; Schendel DJ; Notohamiprodjo M; von Luettichau I; Nelson PJ
    Oncogene; 2006 Mar; 25(10):1496-508. PubMed ID: 16261161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
    Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
    Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.